<DOC>
	<DOC>NCT02356614</DOC>
	<brief_summary>This is a post-approval, multicenter, prospective, non-randomized, open-label, clinical study to evaluate the safety and effectiveness of the LAP-BAND® AP System in a lower obese population (BMI ≥ 30 kg/m2 and &lt; 40 kg/m2) with one or more obesity-related comorbidity up to 10 years after implantation.</brief_summary>
	<brief_title>A Post-approval LAP-BAND® Lower Body Mass Index (LBMI) Study</brief_title>
	<detailed_description>FDA post-approval study designed to collect prospective data in a real-world setting to evaluate long-term safety and effectiveness of the LAP BAND® System in patients with a BMI of ≥ 30 kg/m2 and &lt; 40 kg/m2 and one or more comorbid conditions. The Apollo-001 Study is a prospective, 10 year, multicenter study of patients who have decide to undergo implantation of the LAP-BAND AP® system. Outcomes include device explants, changes in weight, comorbid condition status, device- and procedure-related AEs, and reoperations.</detailed_description>
	<mesh_term>Overweight</mesh_term>
	<criteria>1. LAPBAND® System placed in a facility in the United States 2. BMI ≥ 30 kg/m2 and &lt; 40 kg/m2 prior to LAPBAND® placement 3. Presence of 1 or more obesityrelated comorbidities prior to LAPBAND® placement 4. Aged 18 or older 1. Prior bariatric surgery. 2. Participating in another ongoing clinical study in which concomitant diagnostic or therapeutic intervention that would reasonably be expected to alter patterns of care, use of medications or the outcomes under study. 3. Vulnerable patients or those unable to exercise free informed consent. 4. Inability to complete the questionnaires. 5. Patients who are addicted to alcohol and/or drugs.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Lap Band</keyword>
</DOC>